FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2054634308> ?p ?o ?g. }

• W2054634308 endingPage "604" @default.
• W2054634308 startingPage "599" @default.
• W2054634308 abstract "Gemtuzumab ozogamicin (GO) was approved for marketing in 2000 by the United States Food and Drug Administration (FDA) for older patients with relapsed acute myeloid leukemia (AML). Four months later, 14 phase II clinical trial participants who received novel GO-containing combination chemotherapy regimens developed an unexpected hepatic toxicity termed sinusoidal obstructive syndrome (SOS) or hepatic veno-occlusive disease (VOD). Investigators associated with the Research on Adverse Drug Events and Reports (RADAR) project reviewed safety reports for GO included in reports of clinical trials and observational studies, interim reports from an FDA mandated Prospective Observational Registry, and the Food and Drug Administration's Adverse Event Reporting System. Medline searches provided incidence estimates of GO-associated SOS and comparative rates of SOS without GO. SOS is characterized by hyperbilirubinemia, painful hepatomegaly, ascites, and sudden weight gain developing at a median of 10 days following GO administration for patients who did not undergo an allogeneic SCT procedure and 13 days following an allogeneic SCT for patients who had previously received GO. Among adult AML patients who received GO in clinical trials, SOS incidence was 3% at doses ≤6 mg/m2 if administered as monotherapy or in combination with non-hepatotoxic agents versus 28% if administered with thioguanine and 15% when administered as monotherapy at a dose of 9 mg/m2. Observational studies identified SOS rates between 15% and 40% if an SCT is performed within 3 months of GO administration. The FDA mandated Prospective Observational Registry of patients who receive care at 60 medical centers has identified GO-associated SOS rates of 14% if an SCT is performed and 9% otherwise. Caution is advised when administering GO in routine clinical practice, particularly if administered with other hepatotoxic agents, at doses and schedules more intensive than those approved by the FDA, or within 3 months of a SCT procedure." @default.
• W2054634308 created "2016-06-24" @default.
• W2054634308 creator A5001124933 @default.
• W2054634308 creator A5003177689 @default.
• W2054634308 creator A5009052259 @default.
• W2054634308 creator A5014669541 @default.
• W2054634308 creator A5022508990 @default.
• W2054634308 creator A5037456539 @default.
• W2054634308 creator A5047939331 @default.
• W2054634308 creator A5061285204 @default.
• W2054634308 creator A5064091455 @default.
• W2054634308 creator A5067434226 @default.
• W2054634308 creator A5082924494 @default.
• W2054634308 creator A5089700881 @default.
• W2054634308 date "2007-05-01" @default.
• W2054634308 modified "2023-10-17" @default.
• W2054634308 title "Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An overview from the research on adverse drug events and reports (RADAR) project" @default.
• W2054634308 cites W1575845701 @default.
• W2054634308 cites W1842764967 @default.
• W2054634308 cites W1977847184 @default.
• W2054634308 cites W1991097710 @default.
• W2054634308 cites W1993078113 @default.
• W2054634308 cites W1994871910 @default.
• W2054634308 cites W2007125021 @default.
• W2054634308 cites W2010760749 @default.
• W2054634308 cites W2013264080 @default.
• W2054634308 cites W2051440036 @default.
• W2054634308 cites W2053416351 @default.
• W2054634308 cites W2061960126 @default.
• W2054634308 cites W2065406906 @default.
• W2054634308 cites W2076106584 @default.
• W2054634308 cites W2080001974 @default.
• W2054634308 cites W2084486691 @default.
• W2054634308 cites W2094681262 @default.
• W2054634308 cites W2107943299 @default.
• W2054634308 cites W2129481644 @default.
• W2054634308 cites W2136845772 @default.
• W2054634308 cites W2151475548 @default.
• W2054634308 cites W2167766650 @default.
• W2054634308 cites W2329587176 @default.
• W2054634308 cites W2343183669 @default.
• W2054634308 doi "https://doi.org/10.1016/j.leukres.2006.07.005" @default.
• W2054634308 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16959316" @default.
• W2054634308 hasPublicationYear "2007" @default.
• W2054634308 type Work @default.
• W2054634308 sameAs 2054634308 @default.
• W2054634308 citedByCount "150" @default.
• W2054634308 countsByYear W20546343082012 @default.
• W2054634308 countsByYear W20546343082013 @default.
• W2054634308 countsByYear W20546343082014 @default.
• W2054634308 countsByYear W20546343082015 @default.
• W2054634308 countsByYear W20546343082016 @default.
• W2054634308 countsByYear W20546343082017 @default.
• W2054634308 countsByYear W20546343082018 @default.
• W2054634308 countsByYear W20546343082019 @default.
• W2054634308 countsByYear W20546343082020 @default.
• W2054634308 countsByYear W20546343082021 @default.
• W2054634308 countsByYear W20546343082022 @default.
• W2054634308 countsByYear W20546343082023 @default.
• W2054634308 crossrefType "journal-article" @default.
• W2054634308 hasAuthorship W2054634308A5001124933 @default.
• W2054634308 hasAuthorship W2054634308A5003177689 @default.
• W2054634308 hasAuthorship W2054634308A5009052259 @default.
• W2054634308 hasAuthorship W2054634308A5014669541 @default.
• W2054634308 hasAuthorship W2054634308A5022508990 @default.
• W2054634308 hasAuthorship W2054634308A5037456539 @default.
• W2054634308 hasAuthorship W2054634308A5047939331 @default.
• W2054634308 hasAuthorship W2054634308A5061285204 @default.
• W2054634308 hasAuthorship W2054634308A5064091455 @default.
• W2054634308 hasAuthorship W2054634308A5067434226 @default.
• W2054634308 hasAuthorship W2054634308A5082924494 @default.
• W2054634308 hasAuthorship W2054634308A5089700881 @default.
• W2054634308 hasConcept C10205521 @default.
• W2054634308 hasConcept C120665830 @default.
• W2054634308 hasConcept C121332964 @default.
• W2054634308 hasConcept C126322002 @default.
• W2054634308 hasConcept C176290653 @default.
• W2054634308 hasConcept C177713679 @default.
• W2054634308 hasConcept C197934379 @default.
• W2054634308 hasConcept C23131810 @default.
• W2054634308 hasConcept C2778623314 @default.
• W2054634308 hasConcept C28328180 @default.
• W2054634308 hasConcept C535046627 @default.
• W2054634308 hasConcept C54355233 @default.
• W2054634308 hasConcept C61511704 @default.
• W2054634308 hasConcept C71924100 @default.
• W2054634308 hasConcept C86803240 @default.
• W2054634308 hasConceptScore W2054634308C10205521 @default.
• W2054634308 hasConceptScore W2054634308C120665830 @default.
• W2054634308 hasConceptScore W2054634308C121332964 @default.
• W2054634308 hasConceptScore W2054634308C126322002 @default.
• W2054634308 hasConceptScore W2054634308C176290653 @default.
• W2054634308 hasConceptScore W2054634308C177713679 @default.
• W2054634308 hasConceptScore W2054634308C197934379 @default.
• W2054634308 hasConceptScore W2054634308C23131810 @default.
• W2054634308 hasConceptScore W2054634308C2778623314 @default.
• W2054634308 hasConceptScore W2054634308C28328180 @default.
• W2054634308 hasConceptScore W2054634308C535046627 @default.

• next